FDA to Pay Bonuses for Faster Drug Reviews, Sparking Debate
The FDA is piloting cash bonuses to reward reviewers who finish drug evaluations faster while preserving scientific r...
Find clear guidance on which blue chip coin to start with, including risk notes and a simple starter approach for newcomers.
22,235 articlesThe FDA is piloting cash bonuses to reward reviewers who finish drug evaluations faster while preserving scientific r...
A CPI retreat supplies a rare dose of optimism for markets. This article explores how a hypothetical chair kevin wars...
Bitcoin rebounds past $73,000 as geopolitical tensions roil markets. Analysts caution the move may be temporary, with...
Ripple (XRP) faces a crucial test of its technical footing as it hovers near a key support zone. Traders watch for a ...
Owlet's Q4 2025 results reveal a company balancing growth with a path toward profitability. This article disentangles...
A trading halt and a sharp drop put Lucid in the spotlight, but the company pushed back on bankruptcy chatter. This g...
Jim Cramer signals a clear pecking order in payments, naming Klarna as the one to avoid while highlighting Affirm and...
Goldman Sachs foresees a trillion-dollar space economy within the next two decades, underpinned by commercial growth ...
Adobe sits as a candidate undervalued stock that could rebound in 2026, trading in the low-$280s with a 16x trailing ...
A low-cost S&P 500 ETF has been selected for Trump accounts, with potential inflows of up to $30 billion as investors...
Palantir Technologies stock popped on a rally driven by legal news and AI momentum. This guide explains what happened...
Fed policy under Warsh signals a shift toward real-time data, nudging markets toward the near-term bond curve. Morgan...